Tilray Expands Cannabis Empire Across the Pond

Tilray shares jumped on Tuesday after the company announced that it would be expanding its operations into the United Kingdom.

Published February 9, 2021, 10:23am ET · 2 min read

© IakovKalinin / Getty Images

Tilray Inc. (NASDAQ: TLRY) shares jumped on Tuesday after the company announced that it would be expanding its operations across the pond. Specifically, the firm reached an agreement to distribute its medical cannabis products into the United Kingdom.

Tilray said that it has established an agreement with Grow Pharma to import and distribute its medical cannabis products. This agreement allows Tilray to provide authorized U.K. patients in need with a locally maintained supply of medical cannabis solutions.

As a result, management expects to have a range of GMP-certified, medical cannabis products available for patients in the United Kingdom by March 2021. U.K. Patients looking to use medical cannabis will have access to Tilray products by obtaining prescriptions through private practice or the National Health Service (NHS).

Grow Pharma is a leading U.K. medical cannabis distributor, part of the Grow Group. Tilray is a Canadian-based cannabis grower, and it currently serving tens of thousands of patients and consumers in 17 countries.

[nativounit]

Other cannabis stocks were on the move Tuesday as well. Canopy Growth reported a fiscal third-quarter loss but said it expects to be profitable within a year. Aphria, Aurora Cannabis, Cronos and others saw handy gains on the day as well.

Excluding Tuesday’s move, Tilray stock had outperformed the broad markets with a gain of about 264% year to date. In the past 52 weeks, the stock was up closer to 78%.

Tilray traded up about 25% on Tuesday to $37.65, in a 52-week range of $2.43 to $37.93. The consensus price target is $10.97.

[recirclink id=836909][wallst_email_signup]

Contact [email protected] for any questions or corrections.

Chris Lange

Chris Lange is a financial and geopolitical writer with more than a decade of experience covering a myriad of topics. He has published thousands of articles for 24/7 Wall St., with past coverage focused heavily on stocks, IPOs, healthcare, defense, global affairs, and technology.

His work has been quoted, or referenced by a number of outlets including Business Insider, USA Today, Yahoo Finance, MSN, The Motley Fool, and many other publications. A graduate of Southwestern University, he studied business with a focus on investments and has previous experience in banking and startups.

When not reading or writing the news, he is following his passion for Lacrosse, playing chess, or building solar projects with his dad.

All articles →